Anove-logoAnove-logoExplAIn
KaartenAI-koplopers
Terug naar directory

RetinaLyze

door RetinaLyze

AI Application
Laag vertrouwen

RetinaLyze is cloud software for eye screening, used by optometrists, opticians, eye clinics and hospitals. Retinal photos and OCT scans come in from more than 60 supported cameras and systems; the vendor says a combination of deep learning, convolutional neural networks and rule-based algorithms looks for signs of diabetic retinopathy, glaucoma and age-related macular degeneration and returns a result in about 45 seconds, with overlays and optic-disc measurements such as cup/disc ratio. A yellow alert means further clinical evaluation is recommended and a red alert means referral to an ophthalmologist. The professional adds their clinical judgement to make the final decision, and a built-in telemedicine module lets them consult the vendor's ophthalmologist network or their own and send digital referrals. The vendor says it acts as a data processor, stores images in EU-based cloud storage for as long as the customer is active, and may process data in Denmark and other countries.

Bezoek website

Transparantiescore

Gewogen over vier pijlers · bijgewerkt October 20, 2026

Totaalscore
20% gewogen
ABCDF
Model
—
Nog niet beoordeeld
Infrastructuur
—
Nog niet beoordeeld

Functionaliteiten

Diabetic Retinopathy Screening
Glaucoma Screening
Amd Screening
Optic Disc Measurement
Telemedicine Referral

Leveranciersinformatie

Volledige informatie over de leverancier/provider van deze AI-applicatie

RetinaLyzeBekijk alle producten →
RetinaLyze System A/S(Handelsnaam: RetinaLyze)
Contactinformatie
retinalyze.com
Geregistreerd adres
Lyskær 1, 3. sal, Herlev, Capital Region of Denmark, 2730, DK

Leveranciersinformatie volgens de EU AI Act

Verificatiestatus:
Unverified
RetinaLyze System A/S(Handelsnaam: RetinaLyze)
Lyskær 1, 3. sal, Herlev, Capital Region of Denmark, 2730, DK
Nalevingsdocumenten
CE-markering: Certified
RetinaLyze's FAQ says it does not apply the ICDR, ETDRS or AREDS grading scales and is designed to detect signs of retinal disease rather than replicate manual grading; that its training data come mostly from Scandinavian and European sources; and that it is 'currently transitioning from CE Class I (MDD) to CE Class IIa (MDR)' and is not FDA certified (https://retinalyze.com/faq/, read 2026-10-20). No contraindications are published.
Naleving & risico

Krijg inzicht in risico's door beoordelingen uit te voeren op deze AI-applicatie.

Werk je bij RetinaLyze? Claim deze vermelding om de gegevens te corrigeren of aan te vullen.

Toegevoegd: October 20, 2026
Bijgewerkt: October 20, 2026

Klaar om AI-applicaties te beheren?

Volg, beoordeel en beheer je AI-applicaties met Anove.

Anove-logoAnove-logoAnove International B.V.

We helpen organisaties AI-applicaties op een verantwoorde manier te ontdekken en beheren. Uw betrouwbare bron voor AI-governance en compliance.

Snelle links

  • Directory bekijken
  • FAQ
  • AI-kaarten per sector
  • Inloggen

Bronnen

  • Documentatie
  • Status
  • Anove.ai

Voorwaarden

  • Privacybeleid
  • Algemene voorwaarden
  • Responsible disclosure
  • AI-juridische kennisgeving
  • Beveiligingsbeleid

© 2026 Anove International B.V. Alle rechten voorbehouden.